HENDERSON MICHAEL THOMAS — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

HENDERSON MICHAEL THOMAS has filed 8 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $37.41M.

Profile

HENDERSON MICHAEL THOMAS

Michael Thomas Henderson is the Chief Executive Officer and Director of Apogee Therapeutics, Inc., a biotechnology company focused on developing biologics for various inflammatory and immunology conditions. He has been involved in the company since its early stages, contributing to its strategic direction and growth.

RoleChief Executive Officer, Director
Notability30/100

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-07-11APGEApogee Therapeutics, Inc.G — Bona-fide gift75.0K$0.00
2026-07-11APGEApogee Therapeutics, Inc.S — Open-market sale20.0K$133.63$2.67M
2026-06-25APGEApogee Therapeutics, Inc.S — Open-market sale80.0K$132.54$10.60M
2026-06-24SYRESpyre Therapeutics, Inc.S — Open-market sale20.0K$100.00$2.00M
2026-06-12APGEApogee Therapeutics, Inc.S — Open-market sale614$86.89$53K
2026-06-12APGEApogee Therapeutics, Inc.S — Open-market sale2.3K$86.27$199K
2026-06-12APGEApogee Therapeutics, Inc.S — Open-market sale1.6K$85.19$134K
2026-06-12APGEApogee Therapeutics, Inc.S — Open-market sale1.1K$84.18$91K
2026-06-12APGEApogee Therapeutics, Inc.S — Open-market sale7.7K$82.78$634K
2026-06-12APGEApogee Therapeutics, Inc.S — Open-market sale6.8K$82.21$557K
2026-05-16APGEApogee Therapeutics, Inc.S — Open-market sale1.3K$82.58$111K
2026-05-16APGEApogee Therapeutics, Inc.S — Open-market sale18.7K$82.05$1.53M
2026-05-09SYRESpyre Therapeutics, Inc.S — Open-market sale19.3K$75.35$1.45M
2026-05-09SYRESpyre Therapeutics, Inc.S — Open-market sale24.8K$74.76$1.86M
2026-05-09SYRESpyre Therapeutics, Inc.S — Open-market sale33.5K$73.72$2.47M
2026-05-09SYRESpyre Therapeutics, Inc.S — Open-market sale2.4K$72.57$174K
2026-04-20APGEApogee Therapeutics, Inc.M — Option exercise3.0K$22.86$69K
2026-04-11APGEApogee Therapeutics, Inc.S — Open-market sale [10b5-1]200$85.00$17K
2026-04-11APGEApogee Therapeutics, Inc.S — Open-market sale [10b5-1]2.0K$83.26$167K
2026-04-11APGEApogee Therapeutics, Inc.S — Open-market sale [10b5-1]17.8K$82.48$1.47M

Companies — Last 90 Days

Frequently Asked Questions

Who is HENDERSON MICHAEL THOMAS?

Michael Thomas Henderson is the Chief Executive Officer and Director of Apogee Therapeutics, Inc., a biotechnology company focused on developing biologics for various inflammatory and immunology conditions. He has been involved in the company since its early stages, contributing to its strategic direction and growth.…

How many SEC Form 4 filings has HENDERSON MICHAEL THOMAS submitted recently?

8 primary Form 4 filings in the last 90 days, covering 2 companies.

Has HENDERSON MICHAEL THOMAS been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 37 open-market sales ($37.41M) across all tracked filings.

Where can I see all of HENDERSON MICHAEL THOMAS's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live HENDERSON MICHAEL THOMAS profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.